DELFI Diagnostics, Inc.
The Senior Data Scientist will work with cross-functional teams of scientists, clinicians, engineers, and data scientists to develop statistical analysis methods for early cancer detection assays, supporting assay development, validation, and regulatory submissions. The role involves designing experiments, analyzing data, producing documentation, and providing operational data science support for production monitoring and troubleshooting.
Headquarters
Palo Alto, California, United States
Company Size
51-200 employees
Founded
2019
DELFI Diagnostics is a biotech company focused on saving lives through early cancer detection with blood-based tests. Their platform analyzes cell-free DNA fragmentation patterns using genome-wide sequencing and machine learning to noninvasively detect and localize multiple cancer types from a routine blood draw. DELFI develops tests for screening, diagnosis, and disease monitoring and advances validation through clinical collaborations and trials. The company’s mission is to deliver sensitive, scalable liquid‑biopsy solutions that enable earlier intervention and better outcomes for patients.
DELFI Diagnostics Appoints Cindy Soriano as Chief Financial Officer and Announces Participation in 44th Annual J.P. Morgan Healthcare Conference
Jan 8, 2026
DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting
Apr 25, 2025
DELFI Diagnostics CTO Dr. Amoolya Singh Recognized Among 2025 Most Influential Women in Bay Area Business
May 12, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for DELFI Diagnostics, Inc..
Right around the average for this role
Delfi Diagnostics Announces $225 Million in Series B
Jul 21, 2022